Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats
Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine wh...
Gespeichert in:
Veröffentlicht in: | Biological & pharmaceutical bulletin 2020/05/01, Vol.43(5), pp.859-863 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 863 |
---|---|
container_issue | 5 |
container_start_page | 859 |
container_title | Biological & pharmaceutical bulletin |
container_volume | 43 |
creator | Kondo, Ryo Nakano, Ayuki Asano, Daiki Morita, Akane Arima, Shiho Mori, Asami Sakamoto, Kenji Nagamitsu, Tohru Nakahara, Tsutomu |
description | Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds. |
doi_str_mv | 10.1248/bpb.b19-01065 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2399842490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2399842490</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-c7dc3228896ab590220ca030eb11436d851a87d1b7284f398a60d257e966e2103</originalsourceid><addsrcrecordid>eNpd0c1rFDEYBvAgil2rR68S8OJlar4nOS7rV6GglOo1ZDLvdrPMJGOSUfrfO7tbF_GSEPLjgfd9EHpNyRVlQr_vpu6qo6YhlCj5BK0oF20jGZVP0YoYqhtFpb5AL0rZE0JawvhzdMEZb7VUdIXSuospj27AP1zx8-Ay_raDmOrDBAWvS0k-uAo9_h3qDtcd4LswhniP0xZfxwo5z1MNKR7et1BD_DfpA_yCIU0jxIpDxLeulpfo2dYNBV493pfo-6ePd5svzc3Xz9eb9U3jhVK18W3vOWNaG-U6aQhjxDvCCXSUCq56LanTbU-7lmmx5UY7RXomWzBKAaOEX6J3p9wpp58zlGrHUDwMg4uQ5mIZN0YLJsyBvv2P7tOcl0GOql2MVGJRzUn5nErJsLVTDqPLD5YSe2jCLk3YpQl7bGLxbx5T526E_qz_rn4BmxPYl-ru4QxcrsEPcIwT3MrDcY49__qdyxYi_wMNAZuw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2397249564</pqid></control><display><type>article</type><title>Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Kondo, Ryo ; Nakano, Ayuki ; Asano, Daiki ; Morita, Akane ; Arima, Shiho ; Mori, Asami ; Sakamoto, Kenji ; Nagamitsu, Tohru ; Nakahara, Tsutomu</creator><creatorcontrib>Kondo, Ryo ; Nakano, Ayuki ; Asano, Daiki ; Morita, Akane ; Arima, Shiho ; Mori, Asami ; Sakamoto, Kenji ; Nagamitsu, Tohru ; Nakahara, Tsutomu</creatorcontrib><description>Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b19-01065</identifier><identifier>PMID: 32378561</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>abnormal retinal vasculature ; Angiogenesis ; Animals ; Animals, Newborn ; Arteries ; Blindness ; Capillaries ; Enzyme inhibitors ; Hypoxia ; intravitreal neovascularization ; Neonates ; Phenotype ; Phenotypes ; Phenylurea Compounds - administration & dosage ; Protein Kinase Inhibitors - administration & dosage ; Protein-tyrosine kinase ; Quinazolines - administration & dosage ; Rats, Sprague-Dawley ; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors ; Retina ; Retinal Vessels - drug effects ; Retinal Vessels - growth & development ; Retinal Vessels - pathology ; Signal transduction ; Time Factors ; tortuous artery ; Vascular endothelial growth factor ; vascular endothelial growth factor receptor tyrosine kinase inhibitor ; Vascular endothelial growth factor receptors ; Vascularization</subject><ispartof>Biological and Pharmaceutical Bulletin, 2020/05/01, Vol.43(5), pp.859-863</ispartof><rights>2020 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c466t-c7dc3228896ab590220ca030eb11436d851a87d1b7284f398a60d257e966e2103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32378561$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kondo, Ryo</creatorcontrib><creatorcontrib>Nakano, Ayuki</creatorcontrib><creatorcontrib>Asano, Daiki</creatorcontrib><creatorcontrib>Morita, Akane</creatorcontrib><creatorcontrib>Arima, Shiho</creatorcontrib><creatorcontrib>Mori, Asami</creatorcontrib><creatorcontrib>Sakamoto, Kenji</creatorcontrib><creatorcontrib>Nagamitsu, Tohru</creatorcontrib><creatorcontrib>Nakahara, Tsutomu</creatorcontrib><title>Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats</title><title>Biological & pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds.</description><subject>abnormal retinal vasculature</subject><subject>Angiogenesis</subject><subject>Animals</subject><subject>Animals, Newborn</subject><subject>Arteries</subject><subject>Blindness</subject><subject>Capillaries</subject><subject>Enzyme inhibitors</subject><subject>Hypoxia</subject><subject>intravitreal neovascularization</subject><subject>Neonates</subject><subject>Phenotype</subject><subject>Phenotypes</subject><subject>Phenylurea Compounds - administration & dosage</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein-tyrosine kinase</subject><subject>Quinazolines - administration & dosage</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors</subject><subject>Retina</subject><subject>Retinal Vessels - drug effects</subject><subject>Retinal Vessels - growth & development</subject><subject>Retinal Vessels - pathology</subject><subject>Signal transduction</subject><subject>Time Factors</subject><subject>tortuous artery</subject><subject>Vascular endothelial growth factor</subject><subject>vascular endothelial growth factor receptor tyrosine kinase inhibitor</subject><subject>Vascular endothelial growth factor receptors</subject><subject>Vascularization</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0c1rFDEYBvAgil2rR68S8OJlar4nOS7rV6GglOo1ZDLvdrPMJGOSUfrfO7tbF_GSEPLjgfd9EHpNyRVlQr_vpu6qo6YhlCj5BK0oF20jGZVP0YoYqhtFpb5AL0rZE0JawvhzdMEZb7VUdIXSuospj27AP1zx8-Ay_raDmOrDBAWvS0k-uAo9_h3qDtcd4LswhniP0xZfxwo5z1MNKR7et1BD_DfpA_yCIU0jxIpDxLeulpfo2dYNBV493pfo-6ePd5svzc3Xz9eb9U3jhVK18W3vOWNaG-U6aQhjxDvCCXSUCq56LanTbU-7lmmx5UY7RXomWzBKAaOEX6J3p9wpp58zlGrHUDwMg4uQ5mIZN0YLJsyBvv2P7tOcl0GOql2MVGJRzUn5nErJsLVTDqPLD5YSe2jCLk3YpQl7bGLxbx5T526E_qz_rn4BmxPYl-ru4QxcrsEPcIwT3MrDcY49__qdyxYi_wMNAZuw</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Kondo, Ryo</creator><creator>Nakano, Ayuki</creator><creator>Asano, Daiki</creator><creator>Morita, Akane</creator><creator>Arima, Shiho</creator><creator>Mori, Asami</creator><creator>Sakamoto, Kenji</creator><creator>Nagamitsu, Tohru</creator><creator>Nakahara, Tsutomu</creator><general>The Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20200501</creationdate><title>Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats</title><author>Kondo, Ryo ; Nakano, Ayuki ; Asano, Daiki ; Morita, Akane ; Arima, Shiho ; Mori, Asami ; Sakamoto, Kenji ; Nagamitsu, Tohru ; Nakahara, Tsutomu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-c7dc3228896ab590220ca030eb11436d851a87d1b7284f398a60d257e966e2103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>abnormal retinal vasculature</topic><topic>Angiogenesis</topic><topic>Animals</topic><topic>Animals, Newborn</topic><topic>Arteries</topic><topic>Blindness</topic><topic>Capillaries</topic><topic>Enzyme inhibitors</topic><topic>Hypoxia</topic><topic>intravitreal neovascularization</topic><topic>Neonates</topic><topic>Phenotype</topic><topic>Phenotypes</topic><topic>Phenylurea Compounds - administration & dosage</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein-tyrosine kinase</topic><topic>Quinazolines - administration & dosage</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors</topic><topic>Retina</topic><topic>Retinal Vessels - drug effects</topic><topic>Retinal Vessels - growth & development</topic><topic>Retinal Vessels - pathology</topic><topic>Signal transduction</topic><topic>Time Factors</topic><topic>tortuous artery</topic><topic>Vascular endothelial growth factor</topic><topic>vascular endothelial growth factor receptor tyrosine kinase inhibitor</topic><topic>Vascular endothelial growth factor receptors</topic><topic>Vascularization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kondo, Ryo</creatorcontrib><creatorcontrib>Nakano, Ayuki</creatorcontrib><creatorcontrib>Asano, Daiki</creatorcontrib><creatorcontrib>Morita, Akane</creatorcontrib><creatorcontrib>Arima, Shiho</creatorcontrib><creatorcontrib>Mori, Asami</creatorcontrib><creatorcontrib>Sakamoto, Kenji</creatorcontrib><creatorcontrib>Nagamitsu, Tohru</creatorcontrib><creatorcontrib>Nakahara, Tsutomu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kondo, Ryo</au><au>Nakano, Ayuki</au><au>Asano, Daiki</au><au>Morita, Akane</au><au>Arima, Shiho</au><au>Mori, Asami</au><au>Sakamoto, Kenji</au><au>Nagamitsu, Tohru</au><au>Nakahara, Tsutomu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats</atitle><jtitle>Biological & pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>43</volume><issue>5</issue><spage>859</spage><epage>863</epage><pages>859-863</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>32378561</pmid><doi>10.1248/bpb.b19-01065</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0918-6158 |
ispartof | Biological and Pharmaceutical Bulletin, 2020/05/01, Vol.43(5), pp.859-863 |
issn | 0918-6158 1347-5215 |
language | eng |
recordid | cdi_proquest_miscellaneous_2399842490 |
source | J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
subjects | abnormal retinal vasculature Angiogenesis Animals Animals, Newborn Arteries Blindness Capillaries Enzyme inhibitors Hypoxia intravitreal neovascularization Neonates Phenotype Phenotypes Phenylurea Compounds - administration & dosage Protein Kinase Inhibitors - administration & dosage Protein-tyrosine kinase Quinazolines - administration & dosage Rats, Sprague-Dawley Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Retina Retinal Vessels - drug effects Retinal Vessels - growth & development Retinal Vessels - pathology Signal transduction Time Factors tortuous artery Vascular endothelial growth factor vascular endothelial growth factor receptor tyrosine kinase inhibitor Vascular endothelial growth factor receptors Vascularization |
title | Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T17%3A34%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abnormal%20Vascular%20Phenotypes%20Associated%20with%20the%20Timing%20of%20Interruption%20of%20Retinal%20Vascular%20Development%20in%20Rats&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Kondo,%20Ryo&rft.date=2020-05-01&rft.volume=43&rft.issue=5&rft.spage=859&rft.epage=863&rft.pages=859-863&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b19-01065&rft_dat=%3Cproquest_cross%3E2399842490%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2397249564&rft_id=info:pmid/32378561&rfr_iscdi=true |